David Douglass

Associate Professor

University of Arkansas for Medical Sciences
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Year:

2025

Background In retrospective analyses, the Pediatric Oncology Group [POG) and the Federation National des Centres de Lutte Contre le Cancer (FNCLCC) histologic grade predict outcome in pediatric non‐rhabdomyosarcoma soft tissue sarcoma (NRSTS), but prospective data on grading, clinical features, and outcomes of low‐grade NRSTS are limited. Methods We analyzed patients less than 30 years of age enrolled on Children's Oncology Group (COG) study ARST0332 (NCT00346164) with POG grade 1 or 2 NRSTS. Low‐risk patients were treated with surgery alone. Intermediate‐/high‐risk patients received ifosfamide/doxorubicin and radiotherapy, with definitive resection either before or after 12 weeks of chemoradiotherapy. Results Estimated 5‐year event‐free and overall survival were 90% and 100% low risk ( n = 80), 55% and 78% intermediate risk ( n = 15), and 25% and 25% high risk ( n = 4). In low‐risk patients, only local recurrence was seen in 10%; none with margins greater than 1 mm recurred locally. Sixteen of 17 intermediate‐/high‐risk patients who completed neoadjuvant chemoradiotherapy underwent gross total tumor resection, 80% with negative margins. Intermediate‐/high‐risk group events included one local and seven metastatic recurrences. Had the FNCLCC grading system been used to direct treatment, 29% of low‐risk (surgery alone) patients would have received radiotherapy ± chemotherapy. Conclusions Most low‐risk patients with completely resected POG low‐grade NRSTS are successfully treated with surgery alone, and surgical margins greater than 1 mm may be sufficient to prevent local recurrence. Patients with intermediate‐ and high‐risk low‐grade NRSTS have outcomes similar to patients with high‐grade histology, and require more effective therapies. Use of the current FNCLCC grading system may result in overtreatment of low‐risk NRSTS curable with surgery alone.

Year:

2024

Year:

2023

Collaborators (8)

Sheri L. Spunt

Endowed Professor of Pediatric Cancer

Stanford University School of Medicine

UNITED STATES
View details

Raya Saab

Stanford University

UNITED STATES
View details

Alice Soragni

University of California

UNITED STATES
View details

Ajay Gupta

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jessica L. Davis

Indiana University School of Medicine

UNITED STATES
View details

Alberto Pappo

Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Sapna Oberoi

Associate Professor

University of Manitoba

CANADA
View details

Susan M. Hiniker

Stanford University

UNITED STATES
View details